Zyversa Therapeutics Inc.
ZVSA
All references in this report to ZyVersa, the Company, we, us, or our mean ZyVersa Therapeutics, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Company Overview We are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$24M
▼ -165.1% YoY
Op. Margin
–
ROIC
-1277.14%
▼ -399.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$4M
▲ +32.0% YoY
Net Debt
-$303K
Net Cash Position
Cash & Equiv.
$303K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ZVSA
Zyversa Therapeutics (ZVSA) in two numbers
Questions about Zyversa Therapeutics
Does Zyversa Therapeutics (ZVSA) pay a dividend?
No. Zyversa Therapeutics (ZVSA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 May 2026 (period ending 31 Mar 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ZVSA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ZVSA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.